共 5 条
[1]
Efficacy and tolerability of lisdexamfetamine dimesylate （NRP-104） in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study[J] . Joseph Biederman,Suma Krishnan,Yuxin Zhang,James J. McGough,Robert L. Findling.Clinical Therapeutics . 2007 (3)
[2]
Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release*[J] . James C. Ermer,Amir Shojaei,Michael Pennick,Colleen S. Anderson,Arthur Silverberg,Sharon H. Youcha.Current Medical Research and Opinion? . 2007 (5)
[3]
Is attention‐deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community‐based case–control study[J] . Claudia M.Szobot,Luis A.Rohde,OscarBukstein,Brooke S. G.Molina,CarolineMartins,PaulineRuaro,FlávioPechansky.Addiction . 2007 (7)
[4]
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. McGough JJ,McBurnett K,Bukstein O,et al. Journal of Child and Adolescent Psychopharmacology . 2006
[5]
Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents:update on new stimulant preparations,atomoxetine,and novel treatments. Prince JB. Child Ad-olesc Psychiatr Clin N Am . 2006